These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 15657386)

  • 1. Optimizing percutaneous coronary intervention outcomes: the next steps.
    Vetrovec GW
    Circulation; 2005 Jan; 111(2):125-6. PubMed ID: 15657386
    [No Abstract]   [Full Text] [Related]  

  • 2. [Percutaneous coronary intervention].
    Csapó K
    Orv Hetil; 2005 Mar; 146(13):587-93. PubMed ID: 15856622
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of cardiovascular events after percutaneous coronary intervention.
    Herrmann HC
    N Engl J Med; 2004 Jun; 350(26):2708-10. PubMed ID: 15215488
    [No Abstract]   [Full Text] [Related]  

  • 4. Medical therapy versus percutaneous coronary intervention for patients with stable coronary artery disease.
    Arbab-Zadeh A
    J Am Coll Cardiol; 2009 Feb; 53(6):528-9; author reply 529. PubMed ID: 19195616
    [No Abstract]   [Full Text] [Related]  

  • 5. Drug-eluting stent in saphenous vein graft lesions.
    Kornowski R
    Catheter Cardiovasc Interv; 2008 Jun; 71(7):894-5. PubMed ID: 18498140
    [No Abstract]   [Full Text] [Related]  

  • 6. [Prevention of restenosis and of cardiac events after coronary angioplasty in diabetics].
    Nyssen A; Legrand V; Scheen AJ
    Rev Med Suisse; 2009 Aug; 5(214):1638-43. PubMed ID: 19772194
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Invasive vs non-invasive treatment in acute coronary syndromes and prior bypass surgery.
    Gurfinkel EP; Perez de la Hoz R; Brito VM; Duronto E; Dabbous OH; Gore JM; Anderson FA;
    Int J Cardiol; 2007 Jun; 119(1):65-72. PubMed ID: 17045681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term clinical outcomes of real-world experience using sirolimus-eluting stents in saphenous vein graft disease.
    Ramana RK; Ronan A; Cohoon K; Homan D; Sutherland J; Steen L; Liu J; Loeb H; Lewis BE
    Catheter Cardiovasc Interv; 2008 Jun; 71(7):886-93. PubMed ID: 18412238
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Percutaneous stenting of the left main with drug eluting stents for in-stent restenosis: immediate- and long-term results.
    Mixon T; Fitzsimmons P
    J Invasive Cardiol; 2006 Jun; 18(6):E166-8. PubMed ID: 16775892
    [No Abstract]   [Full Text] [Related]  

  • 10. Applying drug-eluting stents in clinical practice.
    King SB
    Am J Cardiol; 2007 Sep; 100(5A):25K-31K. PubMed ID: 17719350
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Drug-eluting stents--for all, for some or for none?--Editorial].
    Kocka V; Widimský P
    Vnitr Lek; 2007 Oct; 53(10):1033-4. PubMed ID: 18072425
    [No Abstract]   [Full Text] [Related]  

  • 12. Clinical outcomes after multilesion percutaneous coronary intervention: comparison between exclusive and selective use of drug-eluting stents.
    Bertrand OF; Faurie B; Larose E; Nguyen CM; Gleeton O; Déry JP; Noël B; Proulx G; Roy L; Costerousse O; De Larochellière R; Rodés-Cabau J
    J Invasive Cardiol; 2008 Mar; 20(3):99-104. PubMed ID: 18316823
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rescue percutaneous coronary intervention early after coronary artery bypass grafting in the drug-eluting stent era.
    Price MJ; Housman L; Teirstein PS
    Am J Cardiol; 2006 Mar; 97(6):789-91. PubMed ID: 16516577
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) analysis.
    Antman EM; Wiviott SD; Murphy SA; Voitk J; Hasin Y; Widimsky P; Chandna H; Macias W; McCabe CH; Braunwald E
    J Am Coll Cardiol; 2008 May; 51(21):2028-33. PubMed ID: 18498956
    [TBL] [Abstract][Full Text] [Related]  

  • 15. It is never too late for PCI: To relieve medically refractory myocardial ischemia.
    Morrison DA
    Catheter Cardiovasc Interv; 2009 Mar; 73(4):455-6. PubMed ID: 19235234
    [No Abstract]   [Full Text] [Related]  

  • 16. The pathophysiology and burden of restenosis.
    Weintraub WS
    Am J Cardiol; 2007 Sep; 100(5A):3K-9K. PubMed ID: 17719351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hidden drugs, hidden risks--is cocaine use a new risk factor for stent thrombosis?
    Lemos PA
    Catheter Cardiovasc Interv; 2007 Jun; 69(7):959-60. PubMed ID: 17525956
    [No Abstract]   [Full Text] [Related]  

  • 18. Paclitaxel- versus sirolimus-eluting stents for unprotected left main coronary artery disease.
    Mehilli J; Kastrati A; Byrne RA; Bruskina O; Iijima R; Schulz S; Pache J; Seyfarth M; Massberg S; Laugwitz KL; Dirschinger J; Schömig A;
    J Am Coll Cardiol; 2009 May; 53(19):1760-8. PubMed ID: 19422982
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Severe neutropenia under clopidogrel treatment three weeks after coronary stenting.
    Schäfer A; Eigenthaler M; Bauersachs J
    Thromb Haemost; 2007 Feb; 97(2):317-8. PubMed ID: 17264964
    [No Abstract]   [Full Text] [Related]  

  • 20. Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate?
    Bliden KP; DiChiara J; Tantry US; Bassi AK; Chaganti SK; Gurbel PA
    J Am Coll Cardiol; 2007 Feb; 49(6):657-66. PubMed ID: 17291930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.